COMPANY PROFILE

MediMabBio

Explore full profile

Innovative protein therapeutics transforming cancer treatment through scientific excellence and collaboration

South KoreaFounded 2017Biotech & Life Sciences

Valuation $100–250M Last recorded · 2025

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About MediMabBio

MediMabBio, founded in 2017 and based in Seongnam Si, South Korea, is a pioneering biopharmaceutical company specializing in immuno-oncology. The company focuses on developing innovative protein therapeutics, including therapeutic antibodies and fusion proteins, aimed at transforming cancer treatment. MediMabBio operates in the healthcare and biotechnology market, targeting patients with serious health conditions that current therapies cannot adequately address. The company collaborates extensively with the global scientific community to accelerate the pace of discovery and development, embodying an open innovation philosophy. MediMabBio's business model revolves around scientific innovation and collaboration, generating revenue through the development and commercialization of cutting-edge cancer therapies. The company has also been officially approved to join the Vaccine Technology Consultative Body of the Korea Health Industry Development Institute (KHIDI), further solidifying its strong position in the vaccine industry.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2017
Headquarters: South Korea
Employees: 10
Open positions: None listed
Dealroom signal: 62.2/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Oncology, Drug Development, Antibodies, Hard Tech, proteomics, DT and LS, science-based
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES B✓Equity / VC	Nov 2025	$21M	$86M	Union Investment Partners · AON Investment · hlbbiostep.com · SmileGate Investment	↗
GRANT✓Other financing	Sep 2024	$0	—	Korea Tech Incubator Program For Startup	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

MediMabBio website traffic

Latest recorded traffic for MediMabBio is 1.6K monthly website visits, down 48.4% over the last three months. MediMabBio's team grew 0% over the past year.

Latest monthly visits1.6K 3-month web change-48.4% 1-year team growth0%

Monthly website visitsJun 2020–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
NTNexo TherapeuticsUses a combination of covalent ligand discovery and chemical biology to develop new cancer therapies	Golden, United States	Operational	19	$60M	$240M
AUAutotacbioWe believe that the elimination of these	South Korea	Operational
BBBigHat BiosciencesProtein therapeutics company that develops an antibody design platform guided by artificial intelligence	San Carlos, United States	Operational
IBIntrepida BioMonoclonal antibodies targeting BAG3 to combat cancer	San Diego, United States	Closed
PHPhoreMostA new-model drug discovery company based in Cambridge, UK	Pampisford, United Kingdom	Operational
CACantargiaDevelops a therapy for the treatment of cancer by targeting a unique cell-surface receptor on malignant stem cells	Lund Municipality, Sweden	Operational
APAcerta PharmaClinical research on cancer and autoimmune diseases	Oss, Netherlands	Acquired
EXExogeneBiotechnology company accelerating target and TCR discovery for cancer cell therapies using AI-enabled TCR-antigen screening	Oxford, United Kingdom	Operational